The European Medicines Agency EMA has given the green light for an active ingredient for corona therapy in the EU for the first time.
According to the recommendation, certain Covid-19 patients should be allowed to be treated with remdesivir under certain conditions, as the EMA announced in Amsterdam on Thursday. The EU Commission still has to agree, but this is a matter of form.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended conditional approval of the drug for the treatment of adult patients and adolescents aged 12 years and older with pneumonia who require additional oxygen.
Doctors can prescribe the drug to be branded Veklury in Europe after approval.
Remdesivir is seen as a great hope in the treatment of Covid-19 patients and has already been approved for emergency treatment in some countries, including the United States. As a result, its manufacturer, the US biotech group Gilead, has come into focus.
So far, there is no vaccine or medication against the coronavirus that has infected around 9.47 million people worldwide to date, and that almost 482,400? Has claimed fatalities.
– .
